跳至主要内容
临床试验/IRCT20200404046937N5
IRCT20200404046937N5已完成2 期

Evaluation of the therapeutic effect of Remdesivir on COVID-19 patients, A single-arm clinical trial study

Ahvaz University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age =18 years
  • Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19
  • Severe pulmonary involvement in imaging that progresses despite receiving standard treatment protocols within 72 hours of starting antiviral therapy
  • Oxygen saturation less than 90% with canola nasal or respiratory rate more than 30

排除标准

  • Treatment with other antiviral drugs not listed in the national protocol
  • Comorbidities such as malignancy, advanced heart failure, cirrhosis, dialysis patients, stroke, Alzheimer's, advanced neurological disease, progressive respiratory disease
  • Allergic reaction to Remdesivir
  • Pregnant or lactating women
  • Possibility of transfer to another hospital that does not have access to study drugs
  • Evidence of multiple organ failure
  • Receive any experimental treatment for Covid 19
  • Patients under mechanical ventilation at the beginning of the study
  • Alanine Aminotransferase or Aspartate Aminotransferase more than 5 times normal
  • Creatinine clearance less than 50 ml per minute

研究者

相似试验